San Antonio, Texas 78229


Purpose:

Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in HGP following institution of canagliflozin therapy and produce an additive or even synergistic effect to lower the plasma glucose concentration and A1c. Specific Aim 2: To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive, or even synergistic, effect to promote weight loss and reduction in hepatic and visceral fat content. Specific Aim 3. To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive or even synergistic effect to reduce systolic/diastolic blood pressure and 24-hour integrated blood pressure.


Study summary:

Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in HGP following institution of canagliflozin therapy and produce an additive or even synergistic effect to lower the plasma glucose concentration and A1c. We will examine this hypothesis by comparing the effect of administration of liraglutide alone, canagliflozin alone, and the combination of liraglutide plus canagliflozin on:(i) the rate of HGP; (ii) decrease in fasting plasma glucose concentration; (iii) counter-regulatory hormone response and (iv) A1c. We anticipate that the addition of liraglutide to canagliflozin will prevent the increase in plasma glucagon concentration, augment insulin secretion, and blunt/block the increase in HGP in response to canagliflozin, resulting in a greater decrease in fasting plasma glucose concentration and A1c than observed with each therapy alone. Specific Aim 2: To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive, or even synergistic, effect to promote weight loss and reduction in hepatic and visceral fat content. Specific Aim 3. To examine whether combination therapy with liraglutide plus canagliflozin can produce an additive or even synergistic effect to reduce systolic/diastolic blood pressure and 24-hour integrated blood pressure.


Criteria:

Inclusion Criteria: - Male and female subjects between the ages of 18-70 - Subjects with Type 2 Diabetes Mellitus (T2DM) - Drug naïve or on stable dose (more than 3 months) of metformin - Have an HbA1c levels ≥7.0% and <10.0% - Stable weight (± 3 lbs) over the preceding 3 months Exclusion Criteria: - Subjects taking drugs known to affect glucose metabolism (other than metformin) will be excluded. - Individuals with evidence of proliferative diabetic retinopathy or plasma creatinine >1.4 females or >1.5 males or eGFR< 60 ml/min.172m2 will be excluded - Unstable body weight (change of greater than ±3 lbs over the preceding 3 months) - Participates in excessively heavy exercise program


NCT ID:

NCT02324842


Primary Contact:

Principal Investigator
Ralph A DeFronzo, MD
The University of Texas Health Science Center at San Antonio

Ralph A DeFronzo, MD
Phone: 210-567-6691
Email: defronzo@uthscsa.edu


Backup Contact:

Email: cersosimo@uthscsa.edu
Eugenio Cersosimo, MD
Phone: 210-358-7200


Location Contact:

San Antonio, Texas 78229
United States

Ralph A DeFronzo, MD
Phone: 210-567-6691
Email: defronzo@uthscsa.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.